We are live on ! Find out more
PLSE icon

Pulse Biosciences

44 hedge funds and large institutions have $4.38M invested in Pulse Biosciences in 2022 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 12 increasing their positions, 16 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

957% more call options, than puts

Call options by funds: $148K | Put options by funds: $14K

5.99% less ownership

Funds ownership: 14.25%8.26% (-6%)

20% less funds holding

Funds holding: 5544 (-11)

25% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 16

47% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 19

78% less capital invested

Capital invested by funds: $19.9M → $4.38M (-$15.5M)

Holders
44
Holders Change
-11
Holders Change %
-20%
% of All Funds
0.74%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
10
Increased
12
Reduced
16
Closed
19
Calls
$148K
Puts
$14K
Net Calls
+$134K
Net Calls Change
+$122K
Name Holding Trade Value Shares
Change
Change in
Stake
Wells Fargo
26
Wells Fargo
California
$13K -$7.66K -3,045 -26%
CAPTRUST Financial Advisors
27
CAPTRUST Financial Advisors
North Carolina
$13K +$4.45K +1,768 +27%
TRCT
28
Tower Research Capital (TRC)
New York
$6K +$3.77K +1,501 +57%
BNP Paribas Financial Markets
29
BNP Paribas Financial Markets
France
$3.37K +$2.42K +961 +77%
TCWA
30
Ten Capital Wealth Advisors
Washington
$3K
Carson Wealth (CWM LLC)
31
Carson Wealth (CWM LLC)
Nebraska
$2K
Fifth Third Bancorp
32
Fifth Third Bancorp
Ohio
$2K +$551 +219 +24%
Simplex Trading
33
Simplex Trading
Illinois
$2K +$3.71K +1,474 New
Barclays
34
Barclays
United Kingdom
$1K -$4.54K -1,806 -80%
UBS Group
35
UBS Group
Switzerland
$1K +$1.21K +480 +149%
WIM
36
Westside Investment Management
California
$272 +$131K +52,166 +41%
Renaissance Technologies
37
Renaissance Technologies
New York
-$378K -77,824 Closed
Two Sigma Investments
38
Two Sigma Investments
New York
-$290K -59,636 Closed
Bank of New York Mellon
39
Bank of New York Mellon
New York
-$200K -41,208 Closed
N
40
Nuveen
North Carolina
-$186K -36,567 Closed
Charles Schwab
41
Charles Schwab
California
-$150K -30,780 Closed
Marshall Wace
42
Marshall Wace
United Kingdom
-$124K -25,575 Closed
AllianceBernstein
43
AllianceBernstein
Tennessee
-$104K -21,349 Closed
CSS
44
Cubist Systematic Strategies
Connecticut
-$93K -19,186 Closed
Two Sigma Advisers
45
Two Sigma Advisers
New York
-$69K -14,298 Closed
RhumbLine Advisers
46
RhumbLine Advisers
Massachusetts
-$65K -13,340 Closed
New York State Common Retirement Fund
47
New York State Common Retirement Fund
New York
-$24.9K -9,900 -99%
AIG
48
American International Group
New York
-$34K -6,908 Closed
JP Morgan Chase
49
JP Morgan Chase
New York
-$16.4K -6,525 -100%
California State Teachers Retirement System (CalSTRS)
50
California State Teachers Retirement System (CalSTRS)
California
-$29K -5,908 Closed

PLSE Hedge Fund Activity: Q2 2022 in Review

44 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Pulse Biosciences (PLSE) for Q2 2022, worth a combined $4.38M — down 78% from $19.9M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of PLSE and 10 opened new positions — a net loss of 9 holders — while 16 trimmed existing stakes and 12 added.

The largest buyer was Millennium Management, opening a new position worth an estimated $303K. The largest seller was BlackRock, cutting an estimated $1.55M.

  • 44 institutional investors held Pulse Biosciences (PLSE) as of Q2 2022, down from 55 in Q1 2022.
  • Funds reported $4.38M of Pulse Biosciences stock for Q2 2022, down 78% quarter-over-quarter.
  • 10 funds opened new Pulse Biosciences positions in Q2 2022 and 19 closed out, a net change of -9 holders.
  • The largest Pulse Biosciences buyer in Q2 2022 was Millennium Management, an estimated $303K added.
  • The largest Pulse Biosciences seller in Q2 2022 was BlackRock, an estimated $1.55M sold.

Based on aggregated 13F filings for Q2 2022.